On: The field of longevity biotech is a mess

[refurb]

Near-term being key. And most longevity work involves early intervention.

Convincing the FDA you need to dose a 5-year old with an experimental compound so they live until 100 instead of 90 isn't going to work.

[solveit → refurb]

Yes, but you can't convince the FDA to dose a 95-year old either.

[refurb → solveit]

Sure you can if you’re addressing a disease of aging.